Form 4: Eli Lilly Executive Reports Routine Stock Transactions

Eli Lilly's EVP, GC & Secretary, Anat Hakim, reported the vesting of restricted stock units and subsequent sale of shares for tax purposes.

Summary

• Anat Hakim, Executive Vice President, General Counsel & Secretary of Eli Lilly & Co (LLY), reported transactions involving common stock.
• On February 1, 2026, 6,700 Restricted Stock Units (RSUs) vested, converting into 6,700 shares of Eli Lilly common stock at an exercise price of $0.
• Concurrently, 2,953.395 shares of common stock were disposed of at a price of $1,037.15 per share, totaling approximately $3,063,999.94, likely to cover tax obligations related to the RSU vesting.
• Following these transactions, Anat Hakim directly beneficially owns 14,709.105 shares of common stock.
• Indirect beneficial ownership includes 15,700 shares through an Anat Hakim SLAT and 16,875 shares by a spouse, with the reporting person disclaiming beneficial ownership except to the extent of pecuniary interest.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine, pre-scheduled insider transaction related to executive compensation and tax obligations, not indicative of new material information about the company's performance or outlook.

Positives

• The vesting of 6,700 Restricted Stock Units indicates the realization of long-term incentive compensation for a key executive.
• The transaction was pre-planned under a Rule 10b5-1 plan, demonstrating structured and compliant insider trading practices.

Negatives

• A portion of the vested shares (2,953.395 shares) was sold to cover tax liabilities, resulting in a reduction of direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transaction filings like this Form 4 provide transparency into executive compensation and ownership changes, which are standard practices across the pharmaceutical industry. The use of a Rule 10b5-1 plan for these transactions is a common mechanism for executives to manage their equity holdings in a compliant manner.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation practices, which is generally positive for corporate governance.
• Employees: Reflects the standard process for equity compensation vesting and tax handling for executives.

Key Dates

Recommendation

This Form 4 filing details routine, pre-scheduled insider transactions related to executive compensation and tax obligations. It does not provide new material information about Eli Lilly's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining the current investment stance based on broader company fundamentals.

Keywords

Eli Lilly, LLY, Form 4, Insider Transaction, Restricted Stock Units, Executive Compensation, Stock Sale, Tax Withholding, 10b5-1 Plan